Literature DB >> 16516083

Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano.

Stephen J Nicholls1, E Murat Tuzcu, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, Samir Kapadia, Steven E Nissen.   

Abstract

OBJECTIVES: The aim of this study was to determine the relationship between atheroma regression and arterial wall remodeling.
BACKGROUND: Infusion of reconstituted high-density lipoprotein (rHDL) containing recombinant apolipoprotein A-I Milano (AIM) has been reported to promote rapid regression of coronary atherosclerosis. The current study analyzed intravascular ultrasound (IVUS) to define the changes that take place in the arterial wall that accompanied atheroma regression in this study.
METHODS: Forty-seven patients, ages 30 to 75 years, after an acute coronary syndrome were randomized to receive five weekly infusions of placebo or rHDL containing either low- or high-dose AIM. External elastic membrane (EEM) and lumen volumes were compared between coronary IVUS studies at baseline and follow-up.
RESULTS: In comparison with baseline, infusion of rHDL was associated with a 4.6% reduction in EEM volume. Lumen volume did not change. In 10-mm arterial subsegments with the greatest plaque burden at baseline, atheroma volume regressed by 10.9% with a similar reduction in EEM volume but with no change in lumen size. In contrast, EEM and atheroma volume did not change in the 10-mm segments containing the least plaque burden. The reduction in EEM in the most diseased segments was only apparent in subjects who underwent plaque regression. Reduction in EEM volume correlated with the decreased atheroma volume (r = 0.62), but there was no correlation between change in lumen size and change in plaque volume.
CONCLUSIONS: Remodeling of the arterial wall is a focal and heterogeneous process. After infusion of rHDL containing AIM, regression of coronary atherosclerosis is accompanied by reverse remodeling of the EEM, resulting in no change in luminal dimensions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516083     DOI: 10.1016/j.jacc.2005.11.040

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  46 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?

Authors:  Stephen J Nicholls; E Murat Tuzcu; Steven E Nissen
Journal:  Curr Atheroscler Rep       Date:  2007-10       Impact factor: 5.113

Review 3.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Authors:  Mark E Lobatto; Valentin Fuster; Zahi A Fayad; Willem J M Mulder
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

4.  Setting the course for apoAII: a port in sight?

Authors:  Henry J Pownall; Baiba K Gillard; Antonio M Gotto
Journal:  Clin Lipidol       Date:  2013-10

5.  Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.

Authors:  Amar A Sethi; John A Stonik; Fairwell Thomas; Steve J Demosky; Marcelo Amar; Edward Neufeld; H Bryan Brewer; W Sean Davidson; Wilissa D'Souza; Dmitri Sviridov; Alan T Remaley
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

6.  Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.

Authors:  Bernd Hewing; Saj Parathath; Tessa Barrett; Wing Ki Kellie Chung; Yaritzy M Astudillo; Tadateru Hamada; Bhama Ramkhelawon; Thomas C Tallant; Mohamed Shaif S Yusufishaq; Joseph A Didonato; Ying Huang; Jennifer Buffa; Stela Z Berisha; Jonathan D Smith; Stanley L Hazen; Edward A Fisher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-01-09       Impact factor: 8.311

Review 7.  Genetic control of apoprotein A-I and atheroprotection: some insights from inbred strains of mice.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

8.  Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.

Authors:  Yu Kataoka; Jordan Andrews; MyNgan Duong; Tracy Nguyen; Nisha Schwarz; Jessica Fendler; Rishi Puri; Julie Butters; Constance Keyserling; John F Paolini; Jean-Louis Dasseux; Stephen J Nicholls
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

9.  The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Authors:  Fatiha Tabet; Alan T Remaley; Aude I Segaliny; Jonathan Millet; Ling Yan; Shirley Nakhla; Philip J Barter; Kerry-Anne Rye; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

10.  Deficiency of ATP-Binding Cassette Transporters A1 and G1 in Endothelial Cells Accelerates Atherosclerosis in Mice.

Authors:  Marit Westerterp; Kyoichiro Tsuchiya; Ian W Tattersall; Panagiotis Fotakis; Andrea E Bochem; Matthew M Molusky; Vusisizwe Ntonga; Sandra Abramowicz; John S Parks; Carrie L Welch; Jan Kitajewski; Domenico Accili; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-05-19       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.